報價延遲最少15分鐘:2024/12/25 01:20 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.58 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.29/--
|
|
企業價值
27.76M
|
| 資產負債 |
|
每股賬面淨值
0.65
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/25 01:20 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator. |